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Background: Gamma-glutamyltransferase (GGT) regulates apoptotic balance and promotes cancer progression and invasion.
Higher pretherapeutic GGT serum levels have been associated with worse outcomes in various malignancies, but there are no
data for renal cell carcinoma (RCC).
Methods: Pretherapeutic GGT serum levels and clinicopathological parameters were retrospectively evaluated in 921 consecutive
RCC patients treated with nephrectomy at a single institution between 1998 and 2013. Gamma-glutamyltransferase was analysed
as continuous and categorical variable. Associations with RCC-specific survival were assessed with Cox proportional hazards
models. Discrimination was measured with the C-index. Decision-curve analysis was used to evaluate the clinical net benefit. The
median postoperative follow-up was 45 months.
Results: Median pretherapeutic serum GGT level was 25U l 1. Gamma-glutamyltransferase levels increased with advancing T
(Po0.001), N (P¼ 0.006) and M stages (Po0.001), higher grades (Po0.001), and presence of tumour necrosis (Po0.001). An
increase of GGT by 10U l 1 was associated with an increase in the risk of death from RCC by 4% (HR 1.04, Po0.001). Based on
recursive partitioning-based survival tree analysis, we defined four prognostic categories of GGT: normal low (o17.5U l 1), normal
high (17.5 to o34.5U l 1), elevated (34.5 to o181.5U l 1), and highly elevated (X181.5U l 1). In multivariable analyses that
adjusted for the effect of standard features, both continuously and categorically coded GGT were independent prognostic
factors. Adding GGT to a model that included standard features increased the discrimination by 0.9% to 1.8% and improved the
clinical net benefit.
Conclusions: Pretherapeutic serum GGT is a novel and independent prognostic factor for patients with RCC. Stratifying patients
into prognostic subgroups according to GGT may be used for patient counselling, tailoring surveillance, individualised treatment
planning, and clinical trial design.
Renal cell carcinoma (RCC) accounts for490% of kidney cancers
and for 2–3% of all adult malignancies (Jemal et al, 2011). In the
European Union, there were B88 400 new cases and over 39 000
deaths from RCC in 2008 (Ljungberg et al, 2010). Approximately,
20% of patients present with metastatic disease and another 20%
will develop metastases after being considered disease-free (de
Martino et al, 2013; Pichler et al, 2013). Once metastatic, patients
with RCC have a poor prognosis with a median survival time of
B2 years (Procopio et al, 2012). Prognostic factors that identify
patients at an increased risk of recurrence, progression, and
RCC-related death are needed to allow patient stratification into
groups, which would facilitate clinical decision-making regarding
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surveillance scheduling, treatment planning in metastatic disease,
and clinical trial design.
Besides its clinical use as a routine marker for hepatobiliary
disease, studies indicate that the gamma-glutamyltransferase
(GGT) plays an important role in cancer development and cancer
progression (Whitfield, 2001; Corti et al, 2010). Gamma-glutamyl-
transferase is a membrane bound enzyme that is involved in the
glutathione (GSH) metabolism. Glutathione is the main water-
soluble antioxidant within the cell, neutralising reactive oxygen
compounds and free radicals (Pastore et al, 2003). Both GGT and
GSH are regularly elevated in pathological states of oxidative stress
(Whitfield, 2001). In addition, GSH has been linked to tumour
growth and survival, as it is the major provider of cysteine for the
cell. Adequate supply with cysteine is essential for protein
synthesis, especially for fast-dividing neoplastic cells (Hanigan
and Ricketts, 1993). Recently, GGT has gained some attention as a
prognostic biomarker for several types of cancer (Seebacher et al,
2012; Grimm et al, 2013), but there are no reports in RCC to our
knowledge. We hypothesised that GGT plays an important role in
RCC progression and metastasis. To test this, pretherapeutic GGT
levels were associated with survival in a large consecutive cohort of
patients with RCC.
PATIENTS AND METHODS
Institutional review board. The present study was approved by
the institutional review board of the Medical University of Vienna
and the Vienna General Hospital (protocol registration number
1201/2014) and performed according to the REMARK guidelines
(McShane et al, 2005).
Patients. A total of 1287 patients with unilateral sporadic renal
tumours were screened for inclusion in this single centre
retrospective study. All patients underwent radical or partial
nephrectomy for suspected RCC at the Department of Urology,
Comprehensive Cancer Centre, Medical University of Vienna,
Vienna, Austria, between 1998 and 2013.
Patients who were found to have renal tumours other than RCC
(n¼ 219) and those with pre-existing comorbidities or medications
related to elevated GGT (i.e., concomitant malignant disease, acute
or chronic pancreatitis, acute or chronic hepatitis, liver cirrhosis,
intra- or post-hepatic biliary obstruction, cholangitis, congestive
heart failure NYHA III–IV, thyreostatic drugs, anticonvulsants,
and alcohol abuse, n¼ 147) were excluded from the study. The
final cohort comprised 921 patients. Clinical, laboratory, patho-
logical, treatment, and follow-up data of these patients were
extracted from electronic oncology registries.
Therapeutic management. Before surgery, a physical examination
by a consultant in internal medicine and blood tests were
conducted. All patients had a CT scan of the abdomen and an
X-ray or a CT scan of the chest. If symptoms or abnormal
laboratory signs exist, further imaging of the bones and brain was
performed.
None of the patients had preoperative systemic therapy, local
radiotherapy or embolisation. A total of 577 patients (63%)
underwent radical nephrectomy, while 344 (37%) had partial
nephrectomy. Patients with suspicious nodes on imaging or during
the operation underwent a concomitant regional lymph node
dissection (n¼ 155), with a median of four lymph nodes removed
(range 1–25). Every other case was pNx but judged clinical N0. No
patient received adjuvant therapy. Patients were further treated and
generally followed according to the guidelines released by the
European Association of Urology at that time. If patients did not
present for scheduled follow-up visits, they were contacted by
administrative personnel or through the primary care physician.
The median follow-up interval was 45 months (interquartile range,
IQR 19–82). There were 103 deaths from RCC. All patients that
died from RCC had widespread metastatic disease.
Diagnosis of RCC and subtype were established by histological
examination of the surgical specimen according to the World
Health Organization classification. The final T, N, or M stage was
reassigned according to the 2009 Tumour, Node, Metastasis
classification of the Union internationale contre le cancer. T stage
was assigned pathologically and M stage was assigned clinically.
Nuclear grade was assigned according to Fuhrman criteria.
Presence of histological tumour necrosis was recorded prospec-
tively. Over the entire study period, all histological examinations
were performed by three expert uropathologists. Histological slides
from 1998 to 2009 were re-reviewed by one pathologist (AH) for
grade and subtype.
Gamma-glutamyltransferase measurement. Blood samples were
obtained routinely by peripheral venous puncture within 3 days
prior to surgery. All analyses were performed in the central
laboratory of the Medical University of Vienna, which undergoes
regular internal and external quality controls (accreditation
number 0267, EN ISO 15189). Serum GGT levels were measured
at 371C on the day of sample collection. Measurements were
performed with a Roche/Hitachi analyser (Modular Hitachi 747,
Vienna, Austria) until 2008 and with an Olympus 5400 analyser
(Vienna, Austria) thereafter using enzymatic colorimetric assays
(Roche Diagnostics, Vienna, Austria). Gamma-glutamyltransferase
activity was determined at 405 nm using g-L-glutamyl-4-nitroani-
lide as the substrate and glycylglycine as an acceptor, which form
4-nitroanailine. All samples were assayed in duplicate. The intra-
assay coefficient of variation was 2.3%. The normal values for
the enzymatic colorimetric assay were 8–54U l 1 for men and
6–38Ul 1 for women.
Statistical analysis. Gamma-glutamyltransferase levels were pri-
marily analysed as continuous variable and are presented as
medians and IQR. According to histogram plotting and Shapiro–
Wilk statistics, GGT levels were not normally distributed. The
Kruskal–Wallis test was therefore used to assess associations
between GGT and categorical clinicopathological variables.
Correlations were assessed with Spearman’s rank correlation.
The primary point of interest was RCC-specific survival, which
was calculated from the date of surgery to the date of death from
RCC or last follow-up. Cause of death was determined from the
death certificate or the clinical history. Patients who died from
other causes or patients alive were censored with the date of death
or last follow-up, respectively. The date of death and the cause of
death were verified by the Austrian death registry.
Survival probabilities were calculated by the product limit
Kaplan–Meier method, and differences were evaluated with log-
rank tests. Univariable and multivariable Cox regression models
were fitted. Multivariable models adjusted for the effect of standard
prognostic factors including T stage (T3–4 vs T1–2), N stage (Nþ
vs N0), M stage (M1 vs M0), Fuhrman grade (G3–4 vs G1–2),
necrosis (present vs absent), and histologic subtype (clear cell vs
non-clear cell). In addition to a model with continuously coded
GGT, a model with categorically coded GGT was fitted. Cutpoints
for stratification were obtained from the nodes in recursive
partitioning survival tree analysis. Results of Cox models are
presented as hazard ratio (HR), 95% confidence interval (95% CI),
and P-value. Owing to the fairly low numbers of events, there was a
significant risk of overfit in multivariable modelling. Therefore, in
a second set of multivariable analyses, we summarised prognostic
factors with the SSIGN score (Frank et al, 2002) and the University
of California Integrated Staging System (UISS; Zisman et al, 2002).
Multivariable models were internally validated by bootstrapping
(200 re-samples). Schoenfeld’s global test was applied to test the
proportional hazards assumption. Discrimination of Cox models
was assessed with Harrell’s concordance index. Discriminations
GGT in kidney cancer BRITISH JOURNAL OF CANCER
www.bjcancer.com |DOI:10.1038/bjc.2014.450 1527
between nested models were compared with likelihood ratio tests.
Decision-curve analysis was performed to determine whether
models with GGT increased the net benefit over a realistic range of
threshold probabilities compared with the base model. All
statistical testing was two-sided. P-values o0.05 were considered
statistically significant. The statistical package STATA was used for
all analyses.
RESULTS
Clinical and pathological characteristics. Patient characteristics
are shown in Table 1. Median age at the time of surgery was 64 years
(IQR, 55–72). One hundred and thirty patients (14.1%) presented
with lymph node or distant metastases. Further treatment of these
patients following cytoreductive nephrectomy consisted of immuno-
therapy (33.1%), TKI (36.2%), metastasectomy (3.8%) or supportive
care (26.9%). The majority of tumours were clear cell (74.4%).
Association of preoperative serum GGT with clinicopathological
parameters. Median pretherapeutic GGT was 25U l 1 (IQR, 15–
55U l 1). Gamma-glutamyltransferase increased with advancing T
stage (Po0.001) and Fuhrman grade (Po0.001), and was higher in
patients with lymph node metastases (P¼ 0.006), distant metastases
(Po0.001), and tumours with histological tumour necrosis
(Po0.001). Additionally, men had significantly higher GGT levels
than women (Po0.001). In multivariable linear regression analysis,
gender lost its significant association with GGT (P¼ 0.22). There
was no association with histologic subtype (P¼ 0.14) and type of
surgical treatment (P¼ 0.74), and GGT did not correlate with age
(R¼  0.02, P¼ 0.38), pathological tumour size (R¼ 0.003,
P¼ 0.93), body mass index (R¼  0.01, P¼ 0.82), bilirubin levels
(R¼ 0.004, P¼ 0.89), and alkaline phosphatase levels (R¼ 0.028,
P¼ 0.42). There was a statistically significant correlation with AST
(R¼ 0.43, Po0.001) and ALT (R¼ 0.23, Po0.001).
Association of preoperative serum GGT with survival. In
univariable analysis, each 10U l 1 increase in GGT was associated
with a 4% increase in the risk of death from RCC (HR 1.04, 95% CI
1.03–1.05, Po0.001). For substratification, the following four
groups were defined based on the partitioning nodes: normal low
(o17.5U l 1), normal high (17.5 to o34.5U l 1), elevated (34.5
too181.5 U l 1), and highly elevated (X181.5U l 1). Of the 921
patients, 289 (31.4%) had normal low GGT, 315 (34.2%) had
normal high GGT, 296 (32.1%) had elevated, and 21 (2.3%) highly
elevated GGT. These groups differed significantly in terms of RCC-
specific survival (Figure 1). Five-year survival probabilities are
presented in Table 2.
In multivariable analysis that adjusted for the effect of standard
prognostic factors, every 10U l 1 increase in GGT was associated
with a 3% increased risk of death from RCC (P¼ 0.001, Table 3A).
Table 1. Association of GGT with standard clinical and pathological
variables
Variable N (%) Median (IQR; U l1) P
Gender o0.001
Female 332 (36.0) 20 (12–38)
Male 589 (63.9) 28 (18–48)
pT stage o0.001
pT1–2 548 (59.5) 23 (14–38)
pT3–4 373 (40.5) 30 (18–52)
pN stage 0.006
pNx/N0 892 (96.9) 24 (15–43)
pNþ 29 (3.1) 47 (21–92)
M stage o0.001
M0 803 (87.2) 23 (14–40)
M1 118 (12.8) 41 (25–74)
Fuhrman grade o0.001
G1–2 685 (74.4) 23 (14–40)
G3–4 236 (25.6) 30 (19–55)
Tumour necrosis o0.001
Absent 583 (63.3) 22 (14–40)
Present 338 (36.7) 29 (18–49)
Subtype 0.14
Clear cell 685 (74.4) 26 (15–46)
Papillary 160 (17.4) 24 (15–38)
Chromophobe 76 (8.3) 22 (13–40)
Surgical approach 0.74
Radical nephrectomy 577 (62.6) 24 (15–46)
Partial nephrectomy 344 (37.4) 26 (16–41)
Abbreviations: GGT¼gamma-glutamyltransferase; G1-4¼Fuhrman grade 1-4; IQR¼
interquartile range; M¼metastasis; M0¼no distant metastasis; M1¼distant metastasis;
pN¼pathologic lymph node stage; pNx/N0¼ lymph nodes not evaluated/tumour cells
absent from regional lymph nodes; pN+¼presence of lymph node metastasis;
pT¼pathologic tumour stage; pT1-4¼ size and/or extension of primary tumour.
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Figure 1. Kaplan–Meier survival estimates of RCC-specific survival for
921 patients treated with nephrectomy for RCC according to GGT
groups.
Table 2. Categorically coded GGT levels and 5-year RCC-specific survival
rates
Group Reference interval N (%)
Percentage
at 5 years (s.e.)
Normal low o17.5U l 1 289 (31.4) 93.7 (1.9)
Normal high 17.5 to o34.5U l 1 315 (34.2) 87.2 (2.7)
Elevated 34.5 to o181.5U l 1 296 (32.1) 71.6 (3.8)
Highly elevated X181.5U l 1 21 (2.3) 50.0 (12.5)
Abbreviations: GGT¼gamma-glutamyltransferase; RCC¼ renal cell carcinoma.
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In the multivariable model with categorically coded GGT, there was
a continuous increase in the risk of death from RCC with increasing
GGT categories (Table 3A). The base model with the variables T, N,
M stages and nuclear grade, histologic subtype, and tumour necrosis
achieved a discrimination of 88.7%. Inclusion of continuously and
categorically coded GGT increased the discrimination by 0.9%
(P¼ 0.008) and by 1.8% (Po0.001), respectively.
In another set of multivariable analyses, prognostic variables were
summarised as SSIGN score and UISS. Both continuously and
categorically coded GGT were significant prognosticators (Table 3B
and C). The discrimination of the SSIGN score increased after
addition of continuously or categorically coded GGT to the model
(from 88.5% to 89.4%, P¼ 0.003, and from 88.5% to 90.2%,
Po0.001). Likewise, there was a significant increase in discrimination
of UISS with continuously (from 88.2% to 89.7%, Po0.001) and
categorically coded GGT (from 88.2% to 89.9%, Po0.001).
Decision-curve analysis was performed to determine whether
models with GGT increased the net benefit over the base model. In
this analysis, a small net benefit was noted for categorically coded
GGT, while there was no difference in the curves between the base
model and the model with continuously coded GGT (Figure 2).
DISCUSSION
This study shows that pretherapeutic serum GGT is an independent
prognostic factor for patients with RCC, with higher levels being
Table 3.Multivariable Cox regression models for predicting RCC-specific survival of 921 patients treated with surgery for RCC, including (A) models with
single pathological variables and summarised as SSIGN score (B) and UISS (C)
Base model Continuous GGT Categorical GGT
Categories HR 95% CI P HR 95% CI P HR 95% CI P
A
T stage pT3–4 vs pT1–2 2.52 1.48–4.28 0.001 2.42 1.42–4.11 0.001 2.48 1.46–4.19 0.001
N stage pNþ vs pNx/N0 2.22 1.27–3.89 0.005 2.01 1.14–3.54 0.015 1.96 1.08–3.56 0.026
M stage M1 vs M0 15.59 9.64–25.23 o0.001 15.23 9.38–24.72 o0.001 13.80 8.42–22.60 o0.001
Grade G3–4 vs G1–2 1.91 1.24–2.95 0.003 1.96 1.27–3.02 0.002 1.83 1.19–2.82 0.006
Necrosis Present vs absent 1.06 0.69–1.65 0.78 1.11 0.71–1.73 0.65 1.06 0.68–1.65 0.81
Subtype Clear vs not 0.99 0.57–1.73 0.98 0.93 0.54–1.63 0.81 0.88 0.50–1.56 0.67
GGT continuous Continuousa — — — 1.03 1.01–1.05 0.001 — — —
GGT categorical Normal low — — — — — — 1.00
Normal high — — — — — — 1.82 0.96–3.47 0.068
Elevated — — — — — — 3.05 1.66–5.62 o0.001
Highly elevated — — — — — — 5.60 2.17–14.46 o0.001
Discrimination, % 88.7 89.6 90.5
B
SSIGN score Continuous 1.48 1.40–1.55 o0.001 1.45 1.38–1.53 o0.001 1.42 1.35–1.50 o0.001
GGT continuous Continuousa — — — 1.04 1.02–1.06 o0.001 — — —
GGT categorical Normal low — — — — — — 1.00
Normal high — — — — — — 1.98 1.04–3.75 0.036
Elevated — — — — — — 3.37 1.83–6.21 o0.001
Highly elevated — — — — — — 5.98 2.32–15.38 o0.001
Discrimination, % 88.5 89.4 90.2
C
UISS Continuous 3.94 3.30–4.69 o0.001 3.85 3.23–4.59 o0.001 3.56 2.97–4.26 o0.001
GGT continuous Continuousa — — — 1.02 1.01–1.04 0.002 — — —
GGT categorical Normal low — — — — — — 1.00
Normal high — — — — — — 2.02 1.05–3.89 0.035
Elevated — — — — — — 3.49 1.86–6.53 o0.001
Highly elevated — — — — — — 5.95 2.32–15.24 o0.001
Discrimination, % 88.2 89.7 89.9
Abbreviations: CI¼ confidence interval; G1-4¼ Fuhrman grade 1-4. In all analyses, both continuously and categorically coded GGT were significant prognostic factors;
GGT¼gamma-glutamyltransferase; HR¼ hazard ratio; M¼metastasis, M0¼ no distant metastasis; M1¼distant metastasis; pNx/N0¼ lymph nodes not evaluated/tumour cells absent from
regional lymph nodes; pN+¼presence of lymph node metastasis; pT1-4¼ size and/or extension of primary tumour; RCC¼ renal cell carcinoma; SSIGN¼Mayo Clinic Stage, Size, Grade,
and Necrosis; UISS¼University of California Integrated Staging System.
aPer 10U l 1.
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associated with worse outcomes. In addition to statistical signifi-
cance in multivariable analysis, GGT increased the discrimination of
a multivariable base model and improved the clinical net benefit.
Studies indicate that GGT is a prognostic biomarker for several
cancer entities (Polterauer et al, 2011; Seebacher et al, 2012; Grimm
et al, 2013), but data for RCC are limited. Previous studies focused
on GGT levels in relation to metastatic disease, but did not evaluate
survival. Sandock et al (1997) and Simic et al (2007) showed that
GGT is elevated in patients with metastatic disease. In their studies
comprising 82 and 216 patients, respectively, elevated levels of
GGT were independently associated with metastatic disease
irrespective of hepatic involvement. The authors hypothesised that
GGT is increased due to quantitative changes in GGT expression
and necrotic alterations within the tumour. These data are in line
with the current study, which show higher levels of GGT in
patients with advanced tumours and metastases. Ramankulov et al
(2007) were not able to associate GGT with metastatic disease, but
their study comprised only 80 patients. To our knowledge, the
current study is the first to include a survival analysis. We show
that higher serum GGT levels are associated with worse RCC-
specific survival in both univariable and multivariable analyses.
Importantly, categorically coded GGT increased the discrimination
of a multivariable base model by a modest degree and led to an
improvement in the decision-curve analysis.
In the present study, males had significantly higher GGT levels
(median difference 8U l 1) compared to their female counterparts
(Po0.001). It is known that serum levels of GGT differ between
healthy men and women (Schiele et al, 1977), which is reflected in a
higher upper reference interval for men. For healthy individuals in
the 60þ age group, gender differences in GGT are between 6.5 and
17.6U l 1 for healthy individuals. In our RCC cohort, gender was
not a predictor of GGT in the multivariable linear regression model
(P¼ 0.22). Further, although GGT levels commonly increase with
age and BMI (Lee et al, 2007), we found no association between
these two variables and GGT. The variability of GGT in cancer cells
may therefore be linked with an altered cancerous metabolism or the
pivotal role of GGT in carcinogenesis and tumour progression. In
addition, dietary and environmental factors may impact GGT in the
serum and within the tumour, but were not assessed in the current
study. Further prospective translational and basic research studies
should focus on these issues.
For accurate prediction of RCC prognosis, one variable alone is
not sufficient. Therefore, models have been established that
combine several independent prognostic factors. As an example,
the SSIGN score combines T, N, M stages, tumour size, grade, and
necrosis to stratify patients into different risk groups (Frank et al,
2002). The discrimination of the SSIGN score is485%, but it can
be further improved with prognostic biomarkers (Ficarra et al,
2006; de Martino et al, 2012a,b). In the present study, the SSIGN
score and the UISS were used as multivariable base model.
Addition of GGT to the SSIGN score and the UISS revealed
statistical significance and increased its discrimination by a modest
margin. Importantly, addition of categorical GGT led to an
improvement in the net benefit, as an increase in discrimination
does not necessarily equal an improvement in clinical decision-
making. As the SSIGN score was developed for clear cell RCC, the
UISS was used for similar multivariable analyses (Zisman et al,
2002). Here, the discrimination and the increase in discrimination
were comparable. Therefore, both scores appear to be applicable
for prognostic stratification of the current RCC cohort.
In the past years, studies focused on the biology of GGT in
cancer development, progression, and drug resistance. It has been
shown that GGT and subsequently GSH are essential components
of the antioxidant defence by quenching free radicals on DNA
(Whitfield, 2001; Pastore et al, 2003). Through this mechanism, it
is also able to protect cells from cytotoxic damage caused by
various chemotherapeutic drugs (Russo et al, 1986). Further
research revealed a role in assuring the proliferative-apoptotic
balance by exerting pro-oxidant effects at the membrane surface
level and in the extracellular microenvironment (Corti et al, 2010).
By providing cysteine, GSH has been linked with tumour growth
and survival (Hanigan and Ricketts, 1993).
In normal tissue, GGT activity has been shown on the luminal
surface of secretory and absorptive cells including superficial cells
of the bile ducts, bile capillaries, and the brush border membrane
of the proximal tubules of normal kidneys (Fischer et al, 1991;
Hanigan and Frierson, 1996). These surfaces are usually not
connected to the circulation. In contrast, GGT is expressed over
the entire cell surface in RCC (Fischer and Scherberich, 1996;
Kaufmann et al, 1997) and is therefore accessible through the
circulation. This may subsequently lead to elevated serum levels of
GGT and higher intracellular levels of GSH (Lusini et al, 2001),
which correlate with the tumour burden. In fact, GGT levels were
significantly associated with tumour stage, grade, necrosis, and
metastasis, although GGT levels may not be entirely explained by
tumour burden. Further immunohistochemical studies may
provide more information on the relationship between GGT
expression within the tumour and serum levels in RCC patients.
Inadequate validation of potentially strong markers is a major
problem in current biomarker research. As GGT is well established
in clinical practice, subsequent evaluation of its clinical net
benefit as a prognostic marker in patients with RCC in a large
independent prospective cohort needs to be conducted. Thereafter,
introduction of GGT as a clinical routine prognostic marker may
be considered.
Several additional limitations of our study merit to be
mentioned. Owing to the retrospective study design and the long
study period, postoperative imaging and therapy were not
standardised. The therapeutic management for metastatic RCC
has changed within the study period. Compared to immunother-
apy, new targeted therapies have shown superiority in terms of
response and survival (Heng et al, 2013; Kroeger et al, 2013), which
may have impacted our results. Further, the sample size and the
relatively low number of events did not allow any further
subanalyses. Cutpoint values for categorically coded GGT were
ideal for our cohort of RCC patients, but differed slightly from
those used for other malignancies (Strasak et al, 2010; Seebacher
et al, 2012). By accepting cutpoints from other cancers that may
not be perfectly applicable to RCC, the true prognostic value of
GGT may be blurred (Mazumdar and Glassman, 2000). Hence, we
have obtained cutpoints for RCC from the nodes of recursive
partitioning and additionally evaluated GGT as continuously coded
variable without categorisation.
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Figure 2. Decision-curve analysis for predicting RCC-specific survival.
Categorically coded GGT conveyed a small increase in net benefit,
while there was no difference in net benefit between the base model
and the model with continuously coded GGT.
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In summary, we identified pretherapeutic serum GGT as a novel
and independent prognostic biomarker for patients with RCC.
Gamma-glutamyltransferase improves the discrimination of estab-
lished prognostic factors. Stratifying patients into subgroups
according to GGT may be used for patient counselling, tailoring
surveillance, individualised treatment planning, and clinical trial
design. Further validation studies are necessary.
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